Explore the dermatologic drugs the FDA will make a decision to approve during April 2021.
The FDA plans on making a decision on whether to approve 2 new drugs during the month of April. These drugs include benzoyl peroxide (Epsolay, Sol-Gel) for the treatment of papulopustular rosacea (PPR) and abrocitinib (PF-04965842, Pfizer) for the treatment of atopic dermatitis (AD).
Epsolay is a 5% microencapsulated benzoyl peroxide cream, and, if approved, could be the first single-agent benzoyl peroxide prescription drug approved by the FDA, according to a press release form Sol-Gel.1
Sol Gel’s patented microencapsulation technology works by encapsulating the benzoyl peroxide inside porous silica microcapsules, according to the company.2 This generates a barrier between the skin and the drug—with the microcapsules dispensing doses while the barrier reduces benzoyl peroxide’s oxidative effect—the primary cause of skin irritation.
The FDA initially accepted the New Drug Application (NDA) filing for Epsolay in September 2021, and is supported by positive data from 2 phase 3 trials investigating the safety and efficacy of Epsolay in patients with PPR.
In both trials, the benzoyl peroxide topical treatment demonstrated a statistically significant improvement in both co-primary endpoints, including a) a proportion of patients achieving “clear” or “almost clear” according to the Investigator Global Assessment (IGA) scale and b) an absolute mean reduction from baseline in inflammatory lesion count beginning as early as week 2 and held through week 12.1
Additionally, Epsolay showed a favorable safety and tolerability profile comparable to vehicle. The most common adverse reactions occurring in the application were mild to moderate pain, erythema and pruritus, all of which were seen in less than 1% of Epsolay patients.1
Abrocitinib is a once-daily, oral Janus kinases 1 (JAK1) inhibitor for moderate to severe AD in patients 12 years and older. Inhibition of JAK1 is said to influence interleukin (IL)-4, IL-13, IL-22, IL-31 and interferon gamma–all of which are thought to be involved in the pathophysiology of AD.
The drug was granted a Breakthrough Therapy designation from the FDA in February 20183 and given Priority Review designation in October 2020.4
These fillings are supported by positive results from studies in the abrocitinib JAK1 Atopic Dermatitis Efficacy and Safety (JADE) global development program. The submitted studies include JADE MONO-1 and JADE MONO-2, which investigated abrocitinib as a monotherapy; and JADE COMPARE, which evaluated the drug compared to placebo in patients on background topical therapy while also comparing the drug to an active control arm consisting of dupilumab (Dupixent, Sanofi and Regeneron) vs placebo.
In JADE COMPARE5, abrocitinib met all co-primary endpoints and both doses (100 mg and 200 mg) of abrocitinib demonstrated superiority over placebo at week 16 and was sustained until week 16.
Meanwhile, results from JADE MONO-16 also met all co-primary and secondary endpoints, including a proportion of patients who achieved an IGA score of 0 or 1 and at least a 2-point improvement, and a proportion of patients who achieved 75% or more change from baseline in their Eczema Area and Severity Index (EASI) score. Secondary endpoints included a proportion of patients achieving a 4-point or more reduction in itch severity measured with the pruritus numerical rating scale (NRS) and the magnitude of decrease in the Pruritus and Symptoms Assessment for Atopic Dermatitis (PSAAD).
Additionally, results from JADE MONO-27 met all primary and secondary endpoints while demonstrating statistical superiority to placebo. Investigators reported both doses (100 mg and 200 mg) of abrocitinib subjects achieved EASI-75, EASI-90, PP-NRS and IGA responses in a greater proportion vs placebo.